is a copy of the press release, dated August 5, 2026, announcing the results of operations for the fiscal quarter ended June 30, 2026, and guidance for the full year and third quarter of 2026, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities…

is a copy of the press release, dated May 6, 2026, announcing the results of operations for the fiscal quarter ended March 31, 2026, and guidance for the full year and second quarter of 2026, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities…

is a copy of the press release, dated February 24, 2026, announcing the results of operations for the full year and fiscal quarter ended December 31, 2025, and guidance for the full year and first quarter of 2026, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subje…

Costs Associated with Exit or Disposal Activities. On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the “Company”) authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to support margin expansion, optimize the Company’s footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an approximate 300 employees whose positions will be replac…

Regulation FD Disclosure. On December 9, 2025, the Company issued a press release in connection with its 2025 Investor Day announcing the Company’s innovation and financial outlook, including reaffirming its fourth quarter and full year 2025 guidance, and describing other matters including the Restructuring Plan. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed…

is a copy of the press release, dated November 5, 2025, announcing the results of operations for the fiscal quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the lia…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry Into a Material Definitive Agreement. On October 31, 2025, Elanco Animal Health Incorporated (the “Company”) entered into Amendment No. 3 to Credit Agreement (“Amendment No. 3”), by and among the Company, as borrower, Elanco US Inc., as co-borrower, Elanco Financing (Netherlands) B.V., as Dutch borrower, the subsidiary loan parties party thereto, the lenders and the issuing banks party thereto, JPMorgan Chase Bank, N.A., as administrative agent and U.S. and Canadian collateral agent, an…

is a copy of the press release, dated August 7, 2025, announcing the results of operations for the fiscal quarter ended June 30, 2025, and guidance for the full year and third quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities…

Entry into a Material Definitive Agreement. On June 25, 2025, Elanco Animal Health Incorporated (the “Company”), solely in its role as performance guarantor, Elanco SPEAR LLC, as Borrower (the “Borrower”), and Elanco US Inc., as servicer (“Elanco US”), entered into a First Amendment to its Receivables Loan Agreement (as amended, the “Agreement”) with Coöperatieve Rabobank U.A., New York Branch (“Rabobank”), as Administrative Agent, and the lenders from time to time party thereto (“First Amend…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth in

CFO — Robert (Bob) VanHimbergen: The filing announces the appointment of an external CFO to succeed the incumbent, representing a planned executive succession rather than a sudden loss or routine election.

is a copy of the press release, dated May 7, 2025, announcing the results of operations for the fiscal quarter ended March 31, 2025, and guidance for the full year and second quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities…

The provided excerpt is a truncated header and introductory sentence that references a press release but does not contain the specific details of the management change required for classification.

is a copy of the press release, dated February 25, 2025, announcing the results of operations for the full year and fiscal quarter ended December 31, 2024, and guidance for the full year and first quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subje…

Director — Stacey Ma, PhD: The filing discloses the appointment of a new director to the board, which is a routine governance event and not a departure of a senior executive.

is a copy of the press release, dated November 7, 2024, announcing the results of operations for the fiscal quarter ended September 30, 2024, and guidance for the full year and fourth quarter of 2024, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the lia…

Entry into a Material Definitive Agreement. On August 13, 2024 , Elanco Animal Health Incorporated (the “Company”), Elanco US Inc. and certain subsidiaries of the Company entered into an incremental assumption agreement (the “Incremental Assumption Agreement”) with Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent, supplementing and amending the Company’s existing credit agreement (the “Credit Agreement”) dated as of August 1, 202…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth under

is a copy of the press release, dated August 8, 2024, announcing the results of operations for the fiscal quarter ended June 30, 2024, and guidance for the full year and third quarter of 2024, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities…

Completion of Acquisition or Disposition of Assets. As previously disclosed, on February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”) entered into an Asset Purchase Agreement (as amended, modified or supplemented from time to time, the “Purchase Agreement”) with Intervet International B.V., a Dutch private company with limited liability (“Buyer”), pursuant to which Buyer agreed to, subject to the satisfaction or waiver of certain conditions, acquire assets of…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry Into a Material Definitive Agreement. On July 3, 2024, Elanco Animal Health Incorporated (the “Company”) entered into Amendment No. 2 to its Credit Agreement (as amended, the “Credit Agreement”), by and among the Company, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the revolving facility lenders and the issuing banks party thereto, certain exiting revolving facility lenders, JPMorgan Chase Bank, N.A., as revolving facility agent, and Goldman S…

Director — Kathy Turner: The filing describes an administrative re-allocation of board class terms between two directors to effectuate a previously disclosed appointment, with service deemed uninterrupted.

is a copy of the press release, dated May 8, 2024, announcing the results of operations for the fiscal quarter ended March 31, 2024, and guidance for the full year and second quarter of 2024, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities…